Abstract
Our recent studies of the microRNA (miRNA) expression signature in prostate cancer (PCa) indicated that miRNA-218 (miR-218) was significantly downregulated in clinical specimens, suggesting that miR-218 might act as a tumor-suppressive miRNA in PCa. The aim of the present study was to investigate the functional significance of miR-218 in PCa and to identify novel miR-218-regulated cancer pathways and target genes involved in PCa oncogenesis and metastasis. Restoration of miR-218 in PCa cell lines (PC3 and DU145) revealed that this miRNA significantly inhibited cancer cell migration and invasion. Gene expression data and in silico analysis demonstrated that LIM and SH3 protein 1 (LASP1) is a potential target of miR-218 regulation. LASP1 is a cytoskeletal scaffold protein that plays critical roles in cytoskeletal organization and cell migration. Luciferase reporter assays showed that miR-218 directly regulated expression of LASP1. Moreover, downregulating the LASP1 gene significantly inhibited cell migration and invasion in cancer cells, and the expression of LASP1 was upregulated in cancer tissues. We conclude that loss of tumor-suppressive miR-218 enhanced cancer cell migration and invasion in PCa through direct regulation of LASP1. Our data on pathways regulated by tumor-suppressive miR-218 provide new insight into the potential mechanisms of PCa oncogenesis and metastasis.
Keywords: LASP1, microRNA, miR-218, prostate cancer, tumor suppressor
Prostate cancer (PCa) is the most frequently diagnosed cancer and the second leading cause of cancer death among men in developed countries.(1) Most patients are initially responsive to androgen-deprivation therapy (ADT), but their cancers eventually become resistant to ADT and progress to castration-resistant prostate cancer (CRPC). CRPC is difficult to treat, and most clinical trials for advanced PCa have shown limited benefits, with disease progression and metastasis to the skeleton or other sites.(2,3) Therefore, understanding the molecular mechanisms of CRPC and the metastatic pathways underlying PCa using genomic approaches would help to prevent and improve therapies for the disease.
The discovery of non-coding RNAs (ncRNAs) in the human genome was an important conceptual breakthrough in the post-genome sequencing era.(4) Improved understanding of ncRNAs is necessary for continued progress in cancer research. MicroRNAs (miRNAs) are endogenous small ncRNA molecules (19–22 bases in length) that regulate the expression of protein-coding genes by repressing translation or cleaving RNA transcripts in a sequence-specific manner.(5) Currently, 2578 human mature miRNAs are registered at miRBase release 20.0 (http://microrna.sanger.ac.uk/). miRNAs are unique in their ability to regulate multiple protein-coding genes. Bioinformatic predictions indicate that miRNAs regulate >30–60% of the protein-coding genes in the human genome.(6,7)
A significant amount of evidence suggests that miRNAs are aberrantly expressed in many human cancers and that they play significant roles in the initiation, development and metastasis of those cancers.(8,9) Some highly expressed miRNAs can function as oncogenes by repressing tumor suppressors, whereas low-level miRNAs can function as tumor suppressors by negatively regulating oncogenes. It is believed that normal regulatory mechanisms can be disrupted by the aberrant expression of tumor-suppressive or oncogenic miRNAs in cancer cells. Therefore, identification of aberrantly expressed miRNAs is an important first step toward elucidating miRNA-mediated oncogenic pathways.
Based on the foregoing discussion, we have constructed miRNA expression signatures using PCa clinical specimens and investigated the roles of miRNAs in PCa oncogenesis using differentially expressed miRNAs.(10) Recently, we demonstrated that several miRNAs were downregulated in cancer tissues and that miR-1, miR-133a, miR-143 and miR-145 functioned as tumor suppressors by targeting several oncogenic genes.(11,12) Based on our PCa miRNA signature, miR-218 was significantly downregulated, suggesting that this miRNA might be a candidate tumor suppressor in PCa cells. The aim of the present study was to investigate the functional significance of miR-218 in cancer cells and to identify novel miR-218-regulated genes that contributed to PCa oncogenesis and metastasis.
We found that restoration of mature miR-218 inhibited cancer cell migration and invasion, directly targeting LIM and SH3 protein 1 (LASP1). Downregulating the LASP1 significantly inhibited cell migration and invasion by cancer cells. Furthermore, LASP1-regulated novel molecular pathways were investigated through the use of si-LASP1-treated cells. Tumor-suppressive miR-218-LASP1-mediated cancer pathways might provide new insights into the potential mechanisms of PCa oncogenesis and metastasis.
Materials and Methods
Clinical prostate specimens
Seventeen radical prostatectomy specimens were obtained from patients with PCa who underwent treatment at Chiba University Hospital (Chiba, Japan) from 2009 to 2013. Seventeen paired samples of PCa and corresponding normal tissues were used for the present study. The samples considered normal were free of cancer cells as determined by pathologic examination. The patients’ backgrounds and clinico-pathological characteristics are summarized in Table 1. Before tissue collection, all patients provided written informed consent of tissue donation for research purposes. The protocol was approved by the Institutional Review Board of Chiba University.
Table 1.
Patients’ characteristics
| No. | PCa or non-PCa | Age | PSA (ng/mL) | Gleason score | Stage | TNM classification | ||
|---|---|---|---|---|---|---|---|---|
| T | N | M | ||||||
| 1 | PCa | 64 | 5.4 | 3 + 4 | C | 3a | 0 | 0 |
| 2 | PCa | 68 | 12.8 | 3 + 5 | C | 3a | 0 | 0 |
| 3 | PCa | 70 | 16.1 | 4 + 5 | C | 3b | 0 | 0 |
| 4 | PCa | 69 | 25.8 | 4 + 5 | B | 2a | 0 | 0 |
| 5 | PCa | 64 | 29.9 | 4 + 3 | B | 2b | 0 | 0 |
| 6 | PCa | 61 | 7.9 | 3 + 4 | C | 3a | 0 | 0 |
| 7 | PCa | 68 | 8.8 | 4 + 5 | B | 2b | 0 | 0 |
| 8 | PCa | 66 | 6.1 | 4 + 3 | B | 2b | 0 | 0 |
| 9 | PCa | 70 | 11.8 | 4 + 4 | C | 3b | 0 | 0 |
| 10 | PCa | 60 | 22.1 | 3 + 4 | B | 2b | 0 | 0 |
| 11 | PCa | 70 | 8.9 | 3 + 4 | B | 2a | 0 | 0 |
| 12 | PCa | 72 | 4.5 | 3 + 4 | B | 2b | 0 | 0 |
| 13 | PCa | 56 | 7.1 | 3 + 4 | C | 3a | 0 | 0 |
| 14 | PCa | 65 | 13.1 | 4 + 3 | B | 2b | 0 | 0 |
| 15 | PCa | 65 | 9.5 | 4 + 4 | B | 2b | 0 | 0 |
| 16 | PCa | 65 | 5.8 | 4 + 3 | B | 2a | 0 | 0 |
| 17 | PCa | 65 | 4.6 | 5 + 4 | B | 2b | 0 | 0 |
| 1 | Non-PCa | |||||||
| 2 | Non-PCa | |||||||
| 3 | Non-PCa | |||||||
| 4 | Non-PCa | |||||||
| 5 | Non-PCa | |||||||
| 6 | Non-PCa | |||||||
| 7 | Non-PCa | |||||||
| 8 | Non-PCa | |||||||
| 9 | Non-PCa | |||||||
| 10 | Non-PCa | |||||||
| 11 | Non-PCa | |||||||
| 12 | Non-PCa | |||||||
| 13 | Non-PCa | |||||||
| 14 | Non-PCa | |||||||
| 15 | Non-PCa | |||||||
| 16 | Non-PCa | |||||||
| 17 | Non-PCa | |||||||
Cell culture and RNA extraction
PC3 and DU145 cells, human PCa cells obtained from the American Type Culture Collection (Manassas, VA, USA), were maintained in RPMI-1640 medium supplemented with 10% FBS in a humidified atmosphere of 5% CO2 and 95% air at 37°C.
Total RNA was isolated from formalin-fixed paraffin-embedded (FFPE) samples with four 5-μm thick slices, using the miRNeasy FFPE Kit (Qiagen, Hilden, Germany) according to the manufacturer's protocol. RNA quality was confirmed using an Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).
Quantitative real-time RT-PCR
The procedure for PCR quantification was described as previously.(11–13) The TaqMan probes and primers for LASP1 (P/N: Hs01078815_m1 [Applied Biosystems, Foster City, CA, USA]) and for GUSB (the internal control; P/N: Hs00939627_m1 [Applied Biosystems]) were assay-on-demand gene expression products. The expression levels of miR-218 (Assay ID: 000521 [Applied Biosystems]) were analyzed by TaqMan quantitative real-time PCR (TaqMan MicroRNA Assay [Applied Biosystems]) and normalized to the expression of RNU48 (Assay ID: 001006 [Applied Biosystems]). All reactions were performed in triplicate, and each assay included negative control reactions that lacked cDNA.
Transfections with mature microRNA and siRNA
The following mature miRNA species were used in the present study: mature miRNA, Pre-miR miRNA Precursor (has-miR-218; P/N: AM17100 [Applied Biosystems]). The following siRNAs were used: Stealth Select RNAi siRNA, si-LASP1 (P/N: HSS105970 [Invitrogen, Carlsbad, CA, USA]) and negative control miRNA/siRNA (P/N: AM17111 [Applied Biosystems]). RNAs were incubated with OPTI-MEM (Invitrogen) and Lipofectamine RNAiMax reagent (Invitrogen) as described previously. The transfection efficiencies of miRNA in PC3 and DU145 cells were confirmed based on downregulation of TWF1 (PTK9) mRNA following transfection with miR-1 as previously reported.(13)
Cell proliferation, migration and invasion assays
Cells were transfected with 10 nM miRNA or siRNA by reverse transfection and plated in 96-well plates at 3 × 103 cells per well. After 72 h, cell proliferation was determined with the XTT assay using a Cell Proliferation Kit II (Roche Molecular Biochemicals, Mannheim, Germany) as previously reported.(14,15) Cell migration was evaluated with a wound healing assay. Cells were plated in 6-well plates, and the cell monolayers were scraped using a P-20 micropipette tip. The initial gap length (0 h) and the residual gap length 24 h after wounding were calculated from photomicrographs.
A cell invasion assay was carried out using modified Boyden chambers containing Transwell membrane filter inserts (precoated with Matrigel) with 8 μm pores in 24-well tissue culture plates (BD Biosciences, Bedford, MA, USA) at 2 × 105 cells per well. Cells were transfected with 10 nM miRNA or siRNA by reverse transfection and plated in 10-cm dishes at 8 × 105 cells per dish. After 48 h, the cells were collected, and 2 × 105 cells were added to the upper chamber of each migration well.
Cells were allowed to invade for 48 h. After gentle removal of the non-migratory cells from the filter surface of the upper chamber, the cells that invaded into the lower chamber were fixed and stained with Diff-Quick (Sysmex Corporation, Kobe, Japan). The number of cells that migrated to the lower surface was determined microscopically by counting four areas of constant size per well. All experiments were performed in triplicate.
Western blotting
Cells were harvested 72 h after transfection, and lysates were prepared. 50 μg protein lysates were separated on Mini-PROTEAN TGX Gels (Bio-Rad, Hercules, CA, USA) and transferred to PVDF membranes. Immunoblotting was performed with mouse anti-LASP1 antibodies (1:250; HSA012072 [Sigma-Aldrich, St Louis, MO, USA]); anti-GAPDH antibodies (1:1000; ab8245 [Abcam, Cambridge, UK]) were used as an internal loading control.
Screening of miR-218 and LASP1 target genes using in silico analysis and gene expression data
Genes regulated by miR-218 were listed using the TargetScan database as described previously.(14,15) To investigate the expression status of candidate miR-218-target genes in PCa clinical specimens, we examined gene expression profiles in the Gene Expression Omnibus (GEO) database (accession number: GSE29079). In addition, we performed gene expression analysis using miR-218-transfected PC3 cells and si-LASP1-transfected PC3 cells compared to control transfection cells. Oligo-microarray Human 60K (Agilent Technologies) was used for gene expression studies. Microarray procedures and data mining methods were as described previously.(14,15)
Molecular pathway analysis using Kyoto Encyclopedia of Genes and Genomes pathways
To identify molecular signaling pathways regulated by miR-218 or LASP1 in PCa cells, in silico and gene expression data were adapted to Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways categories by the GENECODIS program (http://genecodis.dacya.ucm.es). The strategy of the analysis procedure was described previously.(12)
Plasmid construction and dual-luciferase reporter assay
Partial wild-type sequences of the LASP1 3′-UTR or those with a deleted miR-218 target sites (positions 686-692, 1587-1593 and 2080-2087 of the LASP1 3′-UTR) were inserted between the XhoI–PmeI restriction sites in the 3′-UTR of the hRluc gene in the psiCHECK-2 vector (C8021 [Promega, Madison, WI, USA]). The protocol for vector construction was as described previously.(16) The synthesized DNA was cloned into the psiCHECK-2 vector. PC3 cells were transfected with 50 ng of the vector and 10 nM miR-218 using Lipofectamine 2000 (Invitrogen). The activities of firefly and Renilla luciferases in cell lysates were determined with a dual-luciferase assay system (E1910 [Promega]). Normalized data were calculated as the ratio of Renilla/firefly luciferase activities.
Immunohistochemistry
A total of 17 radical prostatectomy specimens were used (Table 1). Tissue specimens were immunostained following the manufacturer's protocol with the UltraVision Detection System (Thermo Scientific, Fremont, CA, USA). Primary rabbit polyclonal antibodies against LASP1 (Sigma-Aldrich) were diluted 1:500. The slides were treated with biotinylated goat antibodies.
Statistical analysis
The relationships between two groups and the numerical values obtained by real-time RT-PCR were analyzed using the paired t-test. The relationship among three variables and numerical values was analyzed using the Bonferroni-adjusted Mann–Whitney U-test. All analyses were performed using Expert StatView software (version 4; SAS Institute, Cary, NC, USA).
Results
Expression levels of miR-218 in prostate cancer specimens and cell lines
To validate our past miRNA profiling results, we evaluated the expression levels of miR-218 in 17 radical prostatectomy specimens. Quantitative stem-loop RT-PCR demonstrated that miR-218 expression was significantly lower in clinical PCa specimens and PCa cell lines (PC3 and DU145) compared with non-cancerous specimens (Fig. 1). The typical FFPE specimens used for expression analysis in this study are shown in Fig. S1.
Figure 1.
The expression levels of miR-218 in clinical specimens and prostate cancer (PCa) cell lines (PC3 and DU145). Real-time PCR showed that the expression levels of miR-218 were significantly lower in PCa tissues and cell lines than in normal prostate tissues. RNU48 was used as an internal control.
Effects of restoring miR-218 on cell proliferation, migration and invasion activities in prostate cancer cell lines
To investigate the functional effects of miR-218, we performed gain-of-function studies using miRNA transfection of PC3 and DU145 cell lines.
The XTT assay demonstrated that cell proliferation was not inhibited in miR-218 transfectants in comparison with the mock or miR-control transfectant cells (Fig. 2a).
Figure 2.
Effects of miR-218 transfection on prostate cancer (PCa) cell lines (PC3 and DU145). (a) Cell proliferation was determined with XTT assays 72 h after transfection with 10 nM miR-218, miR-control or mock transfection. (b) Cell invasion activity was determined with the Matrigel invasion assay. (c) Cell migration activity determined with the wound healing assay. *P < 0.001.
The Matrigel invasion assay demonstrated that cell invasion activity was significantly inhibited in miR-218 transfectants in comparison with the mock or miR-control transfectant cells (Fig. 2b).
The migration assay demonstrated that cell migration activity was significantly inhibited in miR-218 transfectants in comparison with the mock or miR-control transfectant cells (Fig. 2c).
Identification of candidate genes targeted by miR-218
To gain further insight into the genes affected by miR-218, we analyzed a combination of in silico and gene expression data from PCa clinical specimens. First, we screened miR-218-targeted genes using the TargetScan database and identified 2940 genes. Next, we pared down the 2940 genes based on two kinds of gene expression data as follows: (i) upregulated genes determined by the gene expression dataset of PCa clinical specimens in GEO (accession number: GSE29079); and (ii) downregulated genes (log2 ratio < −1.5) following miR-218 transfection of PC3 cells.
In this selection, we narrowed down the miR-218 target genes for the analysis from 40 genes (Table 2). Five genes (TPD52, ICK, ZHX3, LASP1 and VSIG10) were selected when we paid attention to the numbers of putative target sites of miR-218. Considering which genes are contributing to cancer cell migration and invasion among these five genes, we paid attention to cytoskeleton-regulated genes for control of cancer metastasis according to our previous studies.(13,14) As a result of miR-218 target genes, we focused on the LIM and SH3 protein 1 (LASP1) gene, a cytoskeletal scaffold protein that has critical roles in cytoskeletal organization and cell migration. LASP1 was examined in further analyses.
Table 2.
Candidate of putative miR-218 target genes
| Entrez gene ID | Symbol | Gene name | Location | Fold change | miR-218 transfectant | Conserved sites | Poorly conserved sites |
|---|---|---|---|---|---|---|---|
| 5652 | PRSS8 | Protease, serine, 8 | 16p11.2 | 1.58 | −2.08 | 0 | 1 |
| 7163 | TPD52 | Tumor protein D52 | 8q21 | 1.52 | −2.22 | 2 | 1 |
| 5591 | PRKDC | Protein kinase, DNA-activated, catalytic polypeptide | 8q11 | 1.43 | −1.88 | 0 | 2 |
| 22858 | ICK | Intestinal cell (MAK-like) kinase | 6p12.1 | 1.41 | −2.28 | 2 | 1 |
| 10983 | CCNI | Cyclin I | 4q21.1 | 1.39 | −1.56 | 0 | 1 |
| 8871 | SYNJ2 | Synaptojanin 2 | 6q25.3 | 1.39 | −1.77 | 0 | 1 |
| 5054 | SERPINE1 | Serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1 | 7q22.1 | 1.38 | −2.56 | 0 | 1 |
| 23051 | ZHX3 | Zinc fingers and homeoboxes 3 | 20q12 | 1.33 | −1.74 | 0 | 3 |
| 85414 | SLC45A3 | Solute carrier family 45, member 3 | 1q32.1 | 1.32 | −1.50 | 1 | 0 |
| 80195 | TMEM25 | Transmembrane protein 254 | 10q22.3 | 1.31 | −2.01 | 1 | 0 |
| 9342 | SNAP29 | Synaptosomal-associated protein, 29 kDa | 22q11.21 | 1.30 | −1.91 | 0 | 1 |
| 9289 | GPR56 | G protein-coupled receptor 56 | 16q13 | 1.30 | −2.23 | 0 | 1 |
| 6745 | SSR1 | Signal sequence receptor, alpha | 6p24.3 | 1.30 | −1.63 | 1 | 0 |
| 3927 | LASP1 | LIM and SH3 protein 1 | 17q11-q21.3 | 1.28 | −1.96 | 1 | 2 |
| 54443 | ANLN | Anillin, actin binding protein | 7p15-p14 | 1.26 | −1.82 | 0 | 1 |
| 1824 | DSC2 | Desmocollin 2 | 18q12.1 | 1.25 | −2.33 | 0 | 1 |
| 10447 | FAM3C | Family with sequence similarity 3, member C | 7q31 | 1.24 | −1.92 | 1 | 0 |
| 79443 | FYCO1 | FYVE and coiled-coil domain containing 1 | 3p21.31 | 1.24 | −1.62 | 1 | 0 |
| 4008 | LMO7 | LIM domain 7 | 13q22.2 | 1.22 | −1.75 | 1 | 0 |
| 272 | AMPD3 | Adenosine monophosphate deaminase 3 | 11p15 | 1.22 | −1.57 | 0 | 1 |
| 9725 | TMEM63A | Transmembrane protein 63A | 1q42.12 | 1.21 | −1.64 | 0 | 1 |
| 9917 | FAM20B | Family with sequence similarity 20, member B | 1q25 | 1.21 | −1.63 | 1 | 1 |
| 114908 | TMEM123 | Transmembrane protein 123 | 11q22.1 | 1.19 | −1.69 | 1 | 0 |
| 5781 | PTPN11 | Protein tyrosine phosphatase, non-receptor type 11 | 12q24 | 1.17 | −1.50 | 1 | 0 |
| 5175 | PECAM1 | Platelet/endothelial cell adhesion molecule 1 | 17q23.3 | 1.16 | −1.89 | 0 | 2 |
| 23788 | MTCH2 | Mitochondrial carrier 2 | 11p11.2 | 1.16 | −2.28 | 0 | 2 |
| 79071 | ELOVL6 | ELOVL fatty acid elongase 6 | 4q25 | 1.15 | −2.30 | 0 | 1 |
| 6645 | SNTB2 | Syntrophin, beta 2 (dystrophin-associated protein A1, 59 kDa, basic component 2) | 16q22.1 | 1.15 | −2.34 | 1 | 1 |
| 10613 | ERLIN1 | ER lipid raft associated 1 | 10q24.31 | 1.14 | −1.62 | 0 | 1 |
| 112939 | NACC1 | Nucleus accumbens associated 1, BEN and BTB (POZ) domain containing | 19p13.2 | 1.14 | −1.63 | 2 | 0 |
| 54902 | TTC19 | Tetratricopeptide repeat domain 19 | 17p12 | 1.14 | −1.74 | 0 | 1 |
| 55604 | LRRC16A | Leucine rich repeat containing 16A | 6p22.2 | 1.13 | −2.29 | 0 | 1 |
| 26420 | MAPK9 | Mitogen-activated protein kinase 9 | 11 | 1.13 | −1.51 | 0 | 1 |
| 9497 | SLC4A7 | Solute carrier family 4, sodium bicarbonate cotransporter, member 7 | 3p22 | 1.12 | −1.95 | 0 | 1 |
| 10186 | LHFP | Lipoma HMGIC fusion partner | 13q12 | 1.12 | −1.79 | 2 | 0 |
| 66008 | TRAK2 | Trafficking protein, kinesin binding 2 | 2q33 | 1.10 | −1.67 | 0 | 1 |
| 54621 | VSIG10 | V-set and immunoglobulin domain containing 10 | 12q24.23 | 1.09 | −2.06 | 1 | 2 |
| 357 | SHROOM2 | Shroom family member 2 | Xp22.3 | 1.08 | −1.78 | 0 | 2 |
| 41 | ACCN2 | Acid-sensing (proton-gated) ion channel 1 | 12q12 | 1.08 | −1.51 | 1 | 0 |
| 3248 | HPGD | Hydroxyprostaglandin dehydrogenase 15-(NAD) | 4q34-q35 | 1.02 | −2.54 | 1 | 1 |
LASP1 was a direct target of miR-218 in prostate cells
We performed quantitative real-time RT-PCR and western blotting in PC3 and DU145 cells to investigate whether LASP1 gene expression and LASP1 protein expression were reduced by restoration of miR-218. The mRNA and protein expression levels of LASP1/LASP1 were significantly repressed in miR-218 transfectants in comparison with mock or miR-control transfectants (Fig. 3a,b).
Figure 3.
LASP1 expression was suppressed by miR-218 transfection of prostate cancer (PCa) cells. (a) LASP1 mRNA expression 72 h after transfection with miR-218. GUSB expression was used for normalization. (b) LASP1 protein expression 72 h after transfection with miR-218. GAPDH was used as a loading control. (c) miR-218 binding sites in the 3′-UTR of LASP1 mRNA. Luciferase reporter assays using three vectors encoding putative miR-218 target sites at positions 686–692, 1587–1593 and 2080–2087 for both wild-type and deletion (Del). Renilla luciferase values were normalized to firefly luciferase values, *P < 0.001.
We performed luciferase reporter assays of PC3 to determine whether LASP1 mRNA had target sites for miR-218. The TargetScan database predicted that three putative miR-218-binding sites existed in the 3′-UTR of LASP1 (positions 686–692, 1587–1593 and 2080–2087 [Fig. 3c]). We used vectors encoding either the partial wild-type sequence of the 3′-UTR of LASP1 mRNA, including the predicted miR-218 target sites, or “deletion” vectors; that is, those lacking the miR-218 target sites. We found that the luminescence intensity was significantly reduced by transfection with miR-218 and two vectors carrying the wild-type 3′-UTR of LASP1 (positions 686–692 and 1587–1593), whereas transfection with deletion vectors (where nucleotides at positions 695–691 and 2080–2086 had been removed) blocked the decrease in luminescence (P < 0.001, Fig. 3c). These data suggest that miR-218 bounds directly to two specific binding sites in the 3′-UTR of LASP1 mRNA.
Effects of downregulating LASP1 on cell proliferation, migration and invasion in prostate cancer cell lines
To investigate the functional role of LASP1 in PCa cells, we performed loss-of-function studies using si-LASP1 transfectants. First, we evaluated the knockdown efficiency of si-LASP1 treatments in PC3 and DU145. Quantitative real-time RT-PCR and western blotting indicated that the siRNA effectively downregulated LASP1/LASP1 expression in both cell lines (Fig. 4).
Figure 4.
LASP1 mRNA and LASP1 protein expression levels were suppressed by si-LASP1 transfection of DU145 and PC3 cells. (a) LASP1 mRNA expression 72 h after transfection with si-LASP1. GUSB expression was used for normalization. (b) LASP1 protein expression 72 h after transfection with si-LASP1. GAPDH was used as a loading control. The ratio of LASP1/GAPDH expression was evaluated using ImageJ software (ver. 1.43; http://rsbweb.nih.gov/ij/index.html).
The XTT assay demonstrated that cell proliferation was not inhibited in si-LASP1 transfectants in comparison with the mock or miR-control transfectant cells (Fig. 5a). The Matrigel invasion assay demonstrated that cell invasion activity was significantly inhibited in si-LASP1 transfectants in comparison with the mock or negative control transfectant cells (Fig. 5b). The migration assay demonstrated that cell migration activity was significantly inhibited in si-LASP1 transfectants in comparison with the mock or negative control transfectant cells (Fig. 5c).
Figure 5.
Effects of LASP1 downregulation by si-LASP1 on PCa cells (PC3 and DU145). (a) Cell proliferation determined with the XTT assay. (b) Cell migration activity determined with the wound healing assay. (c) Cell invasion activity determined with the Matrigel invasion assay. *P < 0.001.
Immunohistochemical detection of LASP1 in prostate cancer clinical specimens
We determined the expression levels of LASP1 in PCa specimens by immunohistochemical staining. LASP1 was strongly expressed in several cancer lesions, whereas no or low expression was observed in normal regions (Fig. 6). There was no significant correlation between LASP1 expression and various tested clinicopathological parameters (Gleason score and stages, data not shown).
Figure 6.
Immunohistochemical staining of LASP1 in prostate clinical specimens. Differences in LASP1 expression were observed in cancer lesions and adjacent normal prostate tissues in the same fields: (a) patient number 6; and (b) patient number 16. Overexpression of LASP1 was observed in cancer lesions. In contrast, negative staining of LASP1 in normal prostate glands and stromal tissues (left panel, original magnification ×50; right panel, original magnification ×100).
Identification of novel molecular pathways regulated by LASP1 in prostate cancer cells
To investigate molecular pathways regulated by LASP1, a genome-wide gene expression analysis was performed in PC3 cells. A total of 1269 genes were downregulated in si-LASP1 transfection. Downregulated genes, both si-LASP1-transfectants and miR-218-transfectants (top 18 genes), are shown in Table 3. We also assigned the downregulated genes to KEGG pathways using the GeneCodis program (http://genecodis.cnb.csic.es) as described previously.(12,15) A total of 21 pathways were identified as significantly enriched annotations (Table 4). We focused on the focal adhesion pathway and the genes categorized in this pathway are listed in Table 5.
Table 3.
Downregulated genes both si-LASP1 and miR-218-transfects in PC3 cells
| Entrez gene ID | Symbol | Gene name | Expression (log2 ratio) | |
|---|---|---|---|---|
| miR-218 transfectant | siLASP1 transfectant | |||
| 10529 | NEBL | Nebulette | −2.03 | −3.79 |
| 54757 | FAM20A | Family with sequence similarity 20, member A | −2.09 | −2.93 |
| 3131 | HLF | Hepatic leukemia factor | −4.69 | −2.62 |
| 1381 | CRABP1 | Cellular retinoic acid binding protein 1 | −1.33 | −2.60 |
| 254552 | NUDT8 | Nudix (nucleoside diphosphate linked moiety X)-type motif 8 | −2.57 | −2.53 |
| 4312 | MMP1 | Matrix metallopeptidase 1 (interstitial collagenase) | −0.90 | −2.53 |
| 3927 | LASP1 | LIM and SH3 protein 1 | −1.96 | −2.50 |
| 27151 | CPAMD8 | C3 and PZP-like, alpha-2-macroglobulin domain containing 8 | −0.56 | −2.49 |
| 3866 | KRT15 | Keratin 15 | −3.32 | −2.44 |
| 126823 | KLHDC9 | Kelch domain containing 9 | −0.99 | −2.43 |
| 8722 | CTSF | Cathepsin F | −0.84 | −2.43 |
| 128434 | VSTM2L | V-set and transmembrane domain containing 2 like | 0.00 | −2.35 |
| 3339 | HSPG2 | Heparan sulfate proteoglycan 2 | −2.23 | −2.28 |
| 6678 | SPARC | Secreted protein, acidic, cysteine-rich (osteonectin) | −4.21 | −2.24 |
| 10669 | CGREF1 | Cell growth regulator with EF-hand domain 1 | −0.78 | −2.13 |
| 25890 | ABI3BP | ABI family, member 3 (NESH) binding protein | −2.58 | −2.12 |
| 11093 | ADAMTS13 | ADAM metallopeptidase with thrombospondin type 1 motif, 13 | −0.67 | −2.10 |
| 2171 | FABP5 | Fatty acid binding protein 5 (psoriasis-associated) | −1.58 | −2.09 |
Table 4.
Significantly enriched KEGG pathways regulated by si-LASP1 in PC3 cells
| Number of genes | P-value | Annotations |
|---|---|---|
| 17 | 8E-08 | (KEGG) 04512: ECM-receptor interaction |
| 16 | 7E-05 | (KEGG) 04142: Lysosome |
| 18 | 0.0001 | (KEGG) 05010: Alzheimer's disease |
| 15 | 0.0005 | (KEGG) 04910: Insulin signaling pathway |
| 11 | 0.0006 | (KEGG) 04146: Peroxisome |
| 16 | 0.0008 | (KEGG) 04141: Protein processing in endoplasmic reticulum |
| 18 | 0.0008 | (KEGG) 04510: Focal adhesion |
| 8 | 0.001 | (KEGG) 00280: Valine, leucine and isoleucine degradation |
| 15 | 0.0018 | (KEGG) 00230: Purine metabolism |
| 9 | 0.0046 | (KEGG) 03320: PPAR signaling pathway |
| 15 | 0.0054 | (KEGG) 05016: Huntington's disease |
| 22 | 0.0055 | (KEGG) 05200: Pathways in cancer |
| 6 | 0.0059 | (KEGG) 00640: Propanoate metabolism |
| 10 | 0.0137 | (KEGG) 05146: Amoebiasis |
| 6 | 0.0221 | (KEGG) 00480: Glutathione metabolism |
| 11 | 0.0229 | (KEGG) 00190: Oxidative phosphorylation |
| 11 | 0.023 | (KEGG) 05012: Parkinson's disease |
| 13 | 0.0266 | (KEGG) 04020: Calcium signaling pathway |
| 8 | 0.0382 | (KEGG) 05222: Small cell lung cancer |
| 8 | 0.0482 | (KEGG) 05322: Systemic lupus erythematosus |
| 8 | 0.0492 | (KEGG) 05414: Dilated cardiomyopathy |
KEGG, Kyoto Encyclopedia of Genes and Genomes.
Table 5.
Downregulated genes involved in focal adhesion pathway by si-LASP1 transfectant in PC3 cells
| Entrez Gene ID | Gene symbol | Gene name | Expression (log2 ratio) | |
|---|---|---|---|---|
| miR-218 transfectant | siLASP1 transfectant | |||
| 7791 | ZYX | Zyxin | −0.64 | −0.51 |
| 1288 | COL4A6 | Collagen, type IV, alpha 6 | −0.9 | −0.86 |
| 3913 | LAMB2 | Laminin, beta 2 (laminin S) v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian) | −0.53 | −0.85 |
| 2064 | ERBB2 | −0.63 | −0.91 | |
| 3675 | ITGA3 | Integrin, alpha 3 (antigen CD49C, alpha 3 subunit of VLA-3 receptor) | −0.7 | −0.79 |
| 1287 | COL4A5 | Collagen, type IV, alpha 5 | −0.45 | −0.7 |
| 7148 | TNXB | Tenascin XB | −1.18 | −1.71 |
| 1290 | COL5A2 | Collagen, type V, alpha 2 | 1.57 | −0.82 |
| 25759 | SHC2 | SHC (Src homology 2 domain containing) transforming protein 2 v-akt murine thymoma viral oncogene homolog 1 | 0.72 | −0.85 |
| 207 | AKT1 | −0.52 | −0.53 | |
| 3910 | LAMA4 | Laminin, alpha 4 | 0.49 | −1.07 |
| 5881 | RAC3 | Ras-related C3 botulinum toxin substrate 3 (rho family, small GTP binding protein Rac3) | −0.07 | −0.58 |
| 1292 | COL6A2 | Collagen, type VI, alpha 2 | 0.19 | −1.3 |
| 1289 | COL5A1 | Collagen, type V, alpha 1 | 1.34 | −0.84 |
| 3691 | ITGB4 | Integrin, beta 4 | −0.82 | −1.17 |
| 3912 | LAMB1 | Laminin, beta 1 | 0.2 | −0.58 |
| 7059 | THBS3 | Thrombospondin 3 | −1.2 | −1.09 |
| 5500 | PPP1CB | Protein phosphatase 1, catalytic subunit, beta isozyme | −2.1 | −0.5 |
Discussion
In early stage PCa, most patients initially respond to androgen deprivation therapy; however, many cases become refractory and progress to androgen-independent disease.(2) Currently, there is no effective treatment for hormone-refractory PCa, with disease progression and metastasis to the skeleton or other sites.(3) Thus, new approaches to effective treatments of hormone-refractory PCa are necessary.
In cancer cells, aberrant expression of miRNAs can upset the tightly regulated system of miRNA-protein-coding RNA networks. Therefore, studies of differentially expressed miRNAs in cancer cells provide important information regarding the molecular mechanisms underlying oncogenesis and metastasis. To elucidate the molecular mechanisms underlying PCa, we have examined tumor-suppressive miRNAs, focusing on their regulated molecular targets and novel cancer pathways based on PCa expression signatures.(10) Our recent studies of miRNA expression signatures showed that miR-218 was frequently reduced in other types of cancer tissues and it functioned as a tumor suppressor.(17–19) Tumor-suppressive functions of miR-218 have been described by other research groups analyzing several types of cancers.(20–25) Thus, miR-218 is a key molecule in the development of human cancers, making it important to understand the cancer molecular network that miR-218 regulates. The molecular mechanisms of miR-218 silencing in PCa cells are still unclear. The human genome database indicates that miR-218 is located in two different human chromosome loci (miR-218-1 at 4p15.31 and miR-218-2 at 5q35.1), and these miRNAs are embedded in the intronic regions of SLIT2 and SLIT3, respectively. Previous reports showed that expression of SLIT2 and SLIT3 were downregulated in several types of cancer cells through their promoter hypermethylation.(20,24) Our preliminary examination showed that downregulation of SLIT2 and SLIT3 were observed in primary PCa tissues (Fig. S2). Furthermore, re-expression of SLIT2 and miR-218 were observed after 5-aza-2′-deoxycytidine treatment of PCa cell line (Fig. S3). Thus, our data and previous studies reveal that promoter hypermethylation of SLIT2 and SLIT3 regions drive PCa progression and downregulation of miR-218 in PCa cells.
To better understand PCa metastasis, we identified miR-218 target genes using in silico analysis. As determined by our laboratory and others, the targets of miR-218 include CAV1, LAMB3, ECOP, IKK-B, PXN, RICTOR, BIRC5 and ROBO1.(17,18,20,22–25) Here, we focused on LASP1, a cytoskeletal scaffold protein. It plays critical roles in cytoskeletal organization and cell migration. LASP1 was initially identified in a cDNA library constructed from metastasized breast cancer cells. LASP1 encodes a LIM motif at its N-terminus and a src homology 3 (SH3) domain at its C-terminus.(26,27) The C-terminal SH3 domain of LASP1 functions in protein–protein interactions such as vasodilator-stimulated phosphoprotein, palladin and zyxin.(28–30) Zyxin might function as a messenger in the signal transduction pathway that mediates adhesion-stimulated changes in gene expression and might also modulate the cytoskeletal organization of actin bundles.(30–32) In the present study, we performed genome-wide gene expression analysis using si-LASP1 transfectant PC3 cells to investigate LASP1-regulated molecular targets and pathways. Our data showed that zyxin was downregulated in LASP1-suppressed cells. Zyxin is reportedly regulated by TGF-β and contributes to the epithelial–mesenchymal transition.(31,32) Therefore, it will be important to analyze the molecular mechanisms of LASP1-zyxin signal transduction to better understand the metastasis of human cancer cells.
Overexpression of LASP1 has been reported in metastatic breast and ovarian cancers.(33,34) Our group showed that LASP1 gene expression was elevated in bladder cancer and that downregulation of the LASP1 gene inhibited cancer cell migration and invasion,(16) suggesting that LASP1 significantly contributes to cancer metastasis. This is the first report to show that overexpression of LASP1 in PCa clinical tissues might be involved in the metastasis of PCa. Our previous analysis of bladder cancer showed that tumor-suppressive miRNAs such as miR-1, miR-133a and miR-218 regulated LASP1.(16) Recent studies demonstrated that LASP1 was regulated by miR-203 in breast cancer and esophageal cancer.(35–37) Immunohistchemical staining demonstrated that the overexpression of LASP1 was detected in primary PCa tissues compared with non-PCa tissues. We also measured the expression of miR-218 status using the same FFPE tissues whether the downregulation of miR-218 was associated with upregulation of LASP1 in PCa. Our data showed that expression of miR-218 was significantly reduced in LASP1 overexpression PCa tissues in comparison to LASP1 low staining of non-PCa tissues (Fig. S4). Our data for primary PCa tissues and cell lines might be suggesting that downregulation of miR-218 caused upregulation of LASP1 in PCa cells. Improved understanding of tumor-suppressive miRNAs and their regulation of LASP1 signalling should shed light on PCa metastasis as well as delineate more effective strategies for future therapeutic interventions for this disease.
In conclusion, miR-218 was significantly downregulated in PCa clinical specimens and appeared to function as a tumor suppressor through regulation of oncogenic LASP1. Elucidation of the cancer pathways and target genes regulated by the tumor-suppressive miR-218 should provide new information on potential therapeutic targets in the treatment of PCa metastasis.
Acknowledgments
This study was supported by the KAKENHI (C), 24592590, and (B), 25293333.
Disclosure Statement
The authors have no conflict of interest.
Supporting Information
Additional supporting information may be found in the online version of this article:
Fig. S1. H&E staining of the formalin-fixed paraffin-embedded (FFPE) prostate specimens.
Fig. S2. Expression levels of SLIT2, SLIT3 and miR-218 in prostate cancer (PCa) tissues.
Fig. S3. Effects of 5-aza-2′-deoxycytidine (5-aza-dc) treatment of prostate cancer (PCa) cells.
Fig. S4. Expression levels of miR-218 in prostate cancer (PCa) tissues.
References
- 1.Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11–30. doi: 10.3322/caac.21166. [DOI] [PubMed] [Google Scholar]
- 2.Bott SR, Birtle AJ, Taylor CJ, Kirby RS. Prostate cancer management: 2. An update on locally advanced and metastatic disease. Postgrad Med J. 2003;79:643–5. doi: 10.1136/pmj.79.937.643. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Timsit MO, Lebret T, Mejean A. Chemotherapy of hormonorefractory and hormonoresistant metastatic prostate cancer. Prog Urol. 2008;18(Suppl 7):S365–75. doi: 10.1016/S1166-7087(08)74568-8. [DOI] [PubMed] [Google Scholar]
- 4.Carthew RW, Sontheimer EJ. Origins and mechanisms of miRNAs and siRNAs. Cell. 2009;136:642–55. doi: 10.1016/j.cell.2009.01.035. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Bartel DP. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–97. doi: 10.1016/s0092-8674(04)00045-5. [DOI] [PubMed] [Google Scholar]
- 6.Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: Are the answers in sight? Nat Rev Genet. 2008;9:102–14. doi: 10.1038/nrg2290. [DOI] [PubMed] [Google Scholar]
- 7.Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 2009;19:92–105. doi: 10.1101/gr.082701.108. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Hobert O. Gene regulation by transcription factors and microRNAs. Science. 2008;319:1785–6. doi: 10.1126/science.1151651. [DOI] [PubMed] [Google Scholar]
- 9.Iorio MV, Croce CM. MicroRNAs in cancer: small molecules with a huge impact. J Clin Oncol. 2009;27:5848–56. doi: 10.1200/JCO.2009.24.0317. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Fuse M, Kojima S, Enokida H, et al. Tumor suppressive microRNAs (miR-222 and miR-31) regulate molecular pathways based on microRNA expression signature in prostate cancer. J Hum Genet. 2012;57:691–9. doi: 10.1038/jhg.2012.95. [DOI] [PubMed] [Google Scholar]
- 11.Kojima S, Chiyomaru T, Kawakami K, et al. Tumour suppressors miR-1 and miR-133a target the oncogenic function of purine nucleoside phosphorylase (PNP) in prostate cancer. Br J Cancer. 2012;106:405–13. doi: 10.1038/bjc.2011.462. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Kojima S, Enokida H, Yoshino H, et al. The tumor-suppressive microRNA-143/145 cluster inhibits cell migration and invasion by targeting GOLM1 in prostate cancer. J Hum Genet. 2013 doi: 10.1038/jhg.2013.121. doi: 10.1038/jhg.2013.121. [DOI] [PubMed] [Google Scholar]
- 13.Chiyomaru T, Enokida H, Tatarano S, et al. miR-145 and miR-133a function as tumour suppressors and directly regulate FSCN1 expression in bladder cancer. Br J Cancer. 2010;102:883–91. doi: 10.1038/sj.bjc.6605570. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Yoshino H, Chiyomaru T, Enokida H, et al. The tumour-suppressive function of miR-1 and miR-133a targeting TAGLN2 in bladder cancer. Br J Cancer. 2011;104:808–18. doi: 10.1038/bjc.2011.23. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Nohata N, Hanazawa T, Kikkawa N, et al. Tumour suppressive microRNA-874 regulates novel cancer networks in maxillary sinus squamous cell carcinoma. Br J Cancer. 2011;105:833–41. doi: 10.1038/bjc.2011.311. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Chiyomaru T, Enokida H, Kawakami K, et al. Functional role of LASP1 in cell viability and its regulation by microRNAs in bladder cancer. Urol Oncol. 2012;30:434–43. doi: 10.1016/j.urolonc.2010.05.008. [DOI] [PubMed] [Google Scholar]
- 17.Yamasaki T, Seki N, Yoshino H, et al. MicroRNA-218 inhibits cell migration and invasion in renal cell carcinoma through targeting caveolin-2 involved in focal adhesion pathway. J Urol. 2013;190:1059–68. doi: 10.1016/j.juro.2013.02.089. [DOI] [PubMed] [Google Scholar]
- 18.Yamamoto N, Kinoshita T, Nohata N, et al. Tumor suppressive microRNA-218 inhibits cancer cell migration and invasion by targeting focal adhesion pathways in cervical squamous cell carcinoma. Int J Oncol. 2013;42:1523–32. doi: 10.3892/ijo.2013.1851. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Kinoshita T, Hanazawa T, Nohata N, et al. Tumor suppressive microRNA-218 inhibits cancer cell migration and invasion through targeting laminin-332 in head and neck squamous cell carcinoma. Oncotarget. 2012;3:1386–400. doi: 10.18632/oncotarget.709. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Alajez NM, Lenarduzzi M, Ito E, et al. MiR-218 suppresses nasopharyngeal cancer progression through downregulation of survivin and the SLIT2-ROBO1 pathway. Cancer Res. 2011;71:2381–91. doi: 10.1158/0008-5472.CAN-10-2754. [DOI] [PubMed] [Google Scholar]
- 21.Wu DW, Cheng YW, Wang J, Chen CY, Lee H. Paxillin predicts survival and relapse in non-small cell lung cancer by microRNA-218 targeting. Cancer Res. 2010;70:10392–401. doi: 10.1158/0008-5472.CAN-10-2341. [DOI] [PubMed] [Google Scholar]
- 22.Gao C, Zhang Z, Liu W, Xiao S, Gu W, Lu H. Reduced microRNA-218 expression is associated with high nuclear factor kappa B activation in gastric cancer. Cancer. 2010;116:41–9. doi: 10.1002/cncr.24743. [DOI] [PubMed] [Google Scholar]
- 23.Song L, Huang Q, Chen K, et al. miR-218 inhibits the invasive ability of glioma cells by direct downregulation of IKK-beta. Biochem Biophys Res Commun. 2010;402:135–40. doi: 10.1016/j.bbrc.2010.10.003. [DOI] [PubMed] [Google Scholar]
- 24.Uesugi A, Kozaki K, Tsuruta T, et al. The tumor suppressive microRNA miR-218 targets the mTOR component Rictor and inhibits AKT phosphorylation in oral cancer. Cancer Res. 2011;71:5765–78. doi: 10.1158/0008-5472.CAN-11-0368. [DOI] [PubMed] [Google Scholar]
- 25.Tie J, Pan Y, Zhao L, et al. MiR-218 inhibits invasion and metastasis of gastric cancer by targeting the Robo1 receptor. PLoS Genet. 2010;6:e1000879. doi: 10.1371/journal.pgen.1000879. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Tomasetto C, Moog-Lutz C, Regnier CH, Schreiber V, Basset P, Rio MC. Lasp-1 (MLN 50) defines a new LIM protein subfamily characterized by the association of LIM and SH3 domains. FEBS Lett. 1995;373:245–9. doi: 10.1016/0014-5793(95)01040-l. [DOI] [PubMed] [Google Scholar]
- 27.Tomasetto C, Regnier C, Moog-Lutz C, et al. Identification of four novel human genes amplified and overexpressed in breast carcinoma and localized to the q11–q21.3 region of chromosome 17. Genomics. 1995;28:367–76. doi: 10.1006/geno.1995.1163. [DOI] [PubMed] [Google Scholar]
- 28.Keicher C, Gambaryan S, Schulze E, Marcus K, Meyer HE, Butt E. Phosphorylation of mouse LASP-1 on threonine 156 by cAMP- and cGMP-dependent protein kinase. Biochem Biophys Res Commun. 2004;324:308–16. doi: 10.1016/j.bbrc.2004.08.235. [DOI] [PubMed] [Google Scholar]
- 29.Rachlin AS, Otey CA. Identification of palladin isoforms and characterization of an isoform-specific interaction between Lasp-1 and palladin. J Cell Sci. 2006;119:995–1004. doi: 10.1242/jcs.02825. [DOI] [PubMed] [Google Scholar]
- 30.Li B, Zhuang L, Trueb B. Zyxin interacts with the SH3 domains of the cytoskeletal proteins LIM-nebulette and Lasp-1. J Biol Chem. 2004;279:20401–10. doi: 10.1074/jbc.M310304200. [DOI] [PubMed] [Google Scholar]
- 31.Mori M, Nakagami H, Koibuchi N, et al. Zyxin mediates actin fiber reorganization in epithelial–mesenchymal transition and contributes to endocardial morphogenesis. Mol Biol Cell. 2009;20:3115–24. doi: 10.1091/mbc.E09-01-0046. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Mise N, Savai R, Yu H, Schwarz J, Kaminski N, Eickelberg O. Zyxin is a transforming growth factor-beta (TGF-beta)/Smad3 target gene that regulates lung cancer cell motility via integrin alpha5beta1. J Biol Chem. 2012;287:31393–405. doi: 10.1074/jbc.M112.357624. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Grunewald TG, Kammerer U, Schulze E, et al. Silencing of LASP-1 influences zyxin localization, inhibits proliferation and reduces migration in breast cancer cells. Exp Cell Res. 2006;312:974–82. doi: 10.1016/j.yexcr.2005.12.016. [DOI] [PubMed] [Google Scholar]
- 34.Grunewald TG, Kammerer U, Winkler C, et al. Overexpression of LASP-1 mediates migration and proliferation of human ovarian cancer cells and influences zyxin localisation. Br J Cancer. 2007;96:296–305. doi: 10.1038/sj.bjc.6603545. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Wang C, Zheng X, Shen C, Shi Y. MicroRNA-203 suppresses cell proliferation and migration by targeting BIRC5 and LASP1 in human triple-negative breast cancer cells. J Exp Clin Cancer Res. 2013;31:58. doi: 10.1186/1756-9966-31-58. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.He B, Yin B, Wang B, et al. Overexpression of LASP1 is associated with proliferation, migration and invasion in esophageal squamous cell carcinoma. Oncol Rep. 2013;29:1115–23. doi: 10.3892/or.2012.2199. [DOI] [PubMed] [Google Scholar]
- 37.Takeshita N, Mori M, Kano M, et al. miR-203 inhibits the migration and invasion of esophageal squamous cell carcinoma by regulating LASP1. Int J Oncol. 2012;41:1653–61. doi: 10.3892/ijo.2012.1614. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Fig. S1. H&E staining of the formalin-fixed paraffin-embedded (FFPE) prostate specimens.
Fig. S2. Expression levels of SLIT2, SLIT3 and miR-218 in prostate cancer (PCa) tissues.
Fig. S3. Effects of 5-aza-2′-deoxycytidine (5-aza-dc) treatment of prostate cancer (PCa) cells.
Fig. S4. Expression levels of miR-218 in prostate cancer (PCa) tissues.